NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
84
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
We think Amazon stock is moderately undervalued.
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
We’ve raised our fair value estimate of Apple stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 65.20 | 0.72% |
| CAC 40 | 8,303.15 | 29.31 | 0.35% |
| DAX 40 | 24,950.13 | 228.67 | 0.92% |
| Dow JONES (US) | 50,143.62 | 27.95 | 0.06% |
| FTSE 100 | 10,358.19 | 11.56 | -0.11% |
| HKSE | 27,027.16 | 467.21 | 1.76% |
| NASDAQ | 23,166.31 | 135.09 | 0.59% |
| Nikkei 225 | 56,363.94 | 2,110.26 | 3.89% |
| NZX 50 Index | 13,446.37 | 2.35 | 0.02% |
| S&P 500 | 6,956.17 | 23.87 | 0.34% |
| S&P/ASX 200 | 8,870.10 | 59.20 | 0.67% |
| SSE Composite Index | 4,123.09 | 57.51 | 1.41% |